BR112013008757A2 - composições farmacêuticas que contêm um inibidor de dgat1 - Google Patents
composições farmacêuticas que contêm um inibidor de dgat1 Download PDFInfo
- Publication number
- BR112013008757A2 BR112013008757A2 BR112013008757-9A BR112013008757A BR112013008757A2 BR 112013008757 A2 BR112013008757 A2 BR 112013008757A2 BR 112013008757 A BR112013008757 A BR 112013008757A BR 112013008757 A2 BR112013008757 A2 BR 112013008757A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- sodium
- composition according
- tablet
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39310310P | 2010-10-14 | 2010-10-14 | |
| US61/393,103 | 2010-10-14 | ||
| PCT/US2011/056275 WO2012051488A1 (en) | 2010-10-14 | 2011-10-14 | Pharmaceutical compositions containing a dgat1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013008757A2 true BR112013008757A2 (pt) | 2020-09-01 |
Family
ID=44908106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013008757-9A BR112013008757A2 (pt) | 2010-10-14 | 2011-10-14 | composições farmacêuticas que contêm um inibidor de dgat1 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US20130190354A1 (enExample) |
| EP (1) | EP2627319B1 (enExample) |
| JP (1) | JP6060081B2 (enExample) |
| KR (1) | KR20130100311A (enExample) |
| CN (1) | CN103179957B (enExample) |
| AR (1) | AR083417A1 (enExample) |
| AU (1) | AU2011316003B2 (enExample) |
| BR (1) | BR112013008757A2 (enExample) |
| CA (1) | CA2813781C (enExample) |
| CL (1) | CL2013001001A1 (enExample) |
| CO (1) | CO6710915A2 (enExample) |
| DK (1) | DK2627319T3 (enExample) |
| EC (1) | ECSP13012755A (enExample) |
| ES (1) | ES2712064T3 (enExample) |
| GT (1) | GT201300096A (enExample) |
| HU (1) | HUE043524T2 (enExample) |
| IL (1) | IL225434A0 (enExample) |
| MA (1) | MA34599B1 (enExample) |
| MX (1) | MX2013004162A (enExample) |
| NZ (1) | NZ608558A (enExample) |
| PE (1) | PE20140375A1 (enExample) |
| PH (1) | PH12013500695A1 (enExample) |
| PL (1) | PL2627319T3 (enExample) |
| PT (1) | PT2627319T (enExample) |
| RU (1) | RU2595866C2 (enExample) |
| SG (1) | SG189078A1 (enExample) |
| SI (1) | SI2627319T1 (enExample) |
| TR (1) | TR201902435T4 (enExample) |
| WO (1) | WO2012051488A1 (enExample) |
| ZA (1) | ZA201302108B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013163508A1 (en) * | 2012-04-27 | 2013-10-31 | Novartis Ag | Tetrahydropyran dgat1 inhibitors |
| WO2013169648A1 (en) * | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| MX392182B (es) | 2015-03-13 | 2025-03-21 | Esperion Therapeutics Inc | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| CN107613968A (zh) * | 2015-11-19 | 2018-01-19 | 欣耀生医股份有限公司 | 预防或治疗脂肪肝的药物组合物 |
| KR20250007056A (ko) | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| US10632092B2 (en) | 2017-08-30 | 2020-04-28 | First Fruits Business Ministry, Llc | Composition for and method to increase serum adiponectin and reduce body fat |
| PE20210158A1 (es) | 2018-03-16 | 2021-01-26 | Anji Pharmaceuticals Inc | Composiciones y metodos para tratar el estrenimiento grave |
| US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9611306A (pt) * | 1995-11-14 | 1999-12-28 | Knoll Pharmaceuticals Co | Preparação farmacêutica e, composto farmacêutica estável. |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| DE19816070A1 (de) | 1998-04-09 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden |
| NZ532707A (en) * | 2001-12-21 | 2006-07-28 | Pfizer Prod Inc | Directly compressible formulations of azithromycin |
| MX2007013049A (es) * | 2005-04-19 | 2008-01-11 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad. |
| KR101219042B1 (ko) * | 2005-12-06 | 2013-01-07 | 삼성디스플레이 주식회사 | 반투과형 액정 표시 장치 |
| WO2007078726A2 (en) | 2005-12-16 | 2007-07-12 | Merck & Co., Inc. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
| TW200803850A (en) * | 2006-03-06 | 2008-01-16 | Wyeth Corp | Tablet formulations and processes |
| US20070224258A1 (en) | 2006-03-22 | 2007-09-27 | Bunick Frank J | Dosage forms having a randomized coating |
| PT2402319T (pt) * | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
| NZ577112A (en) | 2006-11-29 | 2012-03-30 | Abbott Lab | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme compirising substituted bicyclic pyrimidines |
| US20080145425A1 (en) * | 2006-12-15 | 2008-06-19 | Pliva Research & Development Limited | Pharmaceutical composition of zolpidem |
| BRPI0810719A8 (pt) | 2007-04-30 | 2016-03-08 | Abbott Lab | Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 |
| US8283331B2 (en) * | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| WO2010114801A1 (en) * | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| SG183529A1 (en) * | 2010-03-30 | 2012-10-30 | Novartis Ag | Uses of dgat1 inhibitors |
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
-
2011
- 2011-10-13 AR ARP110103797A patent/AR083417A1/es unknown
- 2011-10-14 JP JP2013534025A patent/JP6060081B2/ja active Active
- 2011-10-14 DK DK11779278.8T patent/DK2627319T3/en active
- 2011-10-14 PL PL11779278T patent/PL2627319T3/pl unknown
- 2011-10-14 US US13/825,919 patent/US20130190354A1/en not_active Abandoned
- 2011-10-14 EP EP11779278.8A patent/EP2627319B1/en active Active
- 2011-10-14 TR TR2019/02435T patent/TR201902435T4/tr unknown
- 2011-10-14 PE PE2013000837A patent/PE20140375A1/es not_active Application Discontinuation
- 2011-10-14 NZ NZ608558A patent/NZ608558A/en not_active IP Right Cessation
- 2011-10-14 WO PCT/US2011/056275 patent/WO2012051488A1/en not_active Ceased
- 2011-10-14 PH PH1/2013/500695A patent/PH12013500695A1/en unknown
- 2011-10-14 AU AU2011316003A patent/AU2011316003B2/en not_active Ceased
- 2011-10-14 ES ES11779278T patent/ES2712064T3/es active Active
- 2011-10-14 PT PT11779278T patent/PT2627319T/pt unknown
- 2011-10-14 CA CA2813781A patent/CA2813781C/en active Active
- 2011-10-14 SI SI201131677T patent/SI2627319T1/sl unknown
- 2011-10-14 BR BR112013008757-9A patent/BR112013008757A2/pt not_active IP Right Cessation
- 2011-10-14 HU HUE11779278A patent/HUE043524T2/hu unknown
- 2011-10-14 CN CN201180049179.4A patent/CN103179957B/zh active Active
- 2011-10-14 KR KR1020137009333A patent/KR20130100311A/ko not_active Withdrawn
- 2011-10-14 MX MX2013004162A patent/MX2013004162A/es not_active Application Discontinuation
- 2011-10-14 MA MA35806A patent/MA34599B1/fr unknown
- 2011-10-14 RU RU2013121795/15A patent/RU2595866C2/ru active
- 2011-10-14 SG SG2013021944A patent/SG189078A1/en unknown
-
2013
- 2013-03-20 ZA ZA2013/02108A patent/ZA201302108B/en unknown
- 2013-03-21 IL IL225434A patent/IL225434A0/en unknown
- 2013-04-11 CO CO13094273A patent/CO6710915A2/es not_active Application Discontinuation
- 2013-04-11 GT GT201300096A patent/GT201300096A/es unknown
- 2013-04-12 EC ECSP13012755 patent/ECSP13012755A/es unknown
- 2013-04-12 CL CL2013001001A patent/CL2013001001A1/es unknown
-
2015
- 2015-07-22 US US14/805,919 patent/US20150320687A1/en not_active Abandoned
-
2016
- 2016-09-12 US US15/262,056 patent/US20160374947A1/en not_active Abandoned
-
2018
- 2018-05-01 US US15/968,104 patent/US10646446B2/en active Active
-
2020
- 2020-03-31 US US16/835,921 patent/US11304907B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11304907B2 (en) | Pharmaceutical compositions containing a DGAT1 inhibitor | |
| EA022168B1 (ru) | Способ получения уплотненного промежуточного продукта дималеата bibw 2992 и твердые таблетки, полученные из такого продукта | |
| US12350246B2 (en) | Eflornithine and sulindac, fixed dose combination formulation | |
| BRPI0908340A2 (pt) | composição farmacêutica para fármacos pouco solúveis | |
| CN101453992A (zh) | 用于预防心血管事件的双层片剂 | |
| BR112013030093B1 (pt) | comprimido revestido seco de desintegração oral contendo tegafur, gimeracilo e oteracilo potássico | |
| US8613949B2 (en) | Galenical formulations of organic compounds | |
| Kanade et al. | Formulation and evaluation of sublingual tablets of meclizine hydrochloride | |
| HK1184062A (en) | Pharmaceutical compositions containing a dgat1 inhibitor | |
| HK1184062B (en) | Pharmaceutical compositions containing a dgat1 inhibitor | |
| TWI810656B (zh) | 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |